We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.29B
AUM Growth
-$158M
Cap. Flow
-$42M
Cap. Flow %
-1.83%
Top 10 Hldgs %
41.8%
Holding
210
New
13
Increased
53
Reduced
56
Closed
18

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$16.6M
2
ILMN icon
Illumina
ILMN
+$12.9M
3
HUM icon
Humana
HUM
+$10.1M
4
BIIB icon
Biogen
BIIB
+$7.74M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.2M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$18.7M
2
ABT icon
Abbott
ABT
+$15.4M
3
ARRY
Array Biopharma Inc
ARRY
+$15M
4
TMO icon
Thermo Fisher Scientific
TMO
+$13.4M
5
LLY icon
Eli Lilly
LLY
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.94%
2 Real Estate 3.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
151
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.22M 0.05%
+29,125
New +$1.23M
ZLAB icon
152
Zai Lab
ZLAB
$2.06B
$1.21M 0.05%
+37,523
New +$1.29M
OVID icon
153
Ovid Therapeutics
OVID
$442M
$1.21M 0.05%
372,733
– –
MDGL icon
154
Madrigal Pharmaceuticals
MDGL
$11.4B
$1.15M 0.05%
13,340
– –
CLLS
155
Cellectis
CLLS
$287M
$1.15M 0.05%
110,147
– –
SNR
156
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$1.06M 0.05%
158,047
– –
DPLO
157
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$1.05M 0.05%
214,845
– –
MYOK
158
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.01M 0.04%
19,300
-19,300
-50% -$1.03M
ALLK
159
DELISTED
Allakos
ALLK
$960K 0.04%
12,207
-12,207
-50% -$806K
SPPI
160
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$951K 0.04%
114,670
– –
MTEM
161
DELISTED
Molecular Templates, Inc.
MTEM
$950K 0.04%
9,607
– –
FOMX
162
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$914K 0.04%
300,781
– –
TBPH icon
163
Theravance Biopharma
TBPH
$873M
$898K 0.04%
+46,101
New +$931K
ARWR icon
164
Arrowhead Research
ARWR
$12.3B
$865K 0.04%
30,700
– –
ACIU icon
165
AC Immune
ACIU
$241M
$850K 0.04%
171,813
– –
XRN
166
Chiron Real Estate Inc
XRN
$516M
$837K 0.04%
14,680
– –
MIST icon
167
Milestone Pharmaceuticals
MIST
$143M
$812K 0.04%
46,940
-3,060
-6% -$60.2K
PBYI icon
168
Puma Biotechnology
PBYI
$402M
$768K 0.03%
71,340
– –
NTLA icon
169
Intellia Therapeutics
NTLA
$1.55B
$735K 0.03%
55,050
-95,240
-63% -$1.52M
CYH icon
170
Community Health Systems
CYH
$391M
$734K 0.03%
203,935
– –
PRGO icon
171
Perrigo
PRGO
$1.43B
$605K 0.03%
10,818
-10,900
-50% -$555K
ARQL
172
DELISTED
Arqule Inc
ARQL
$545K 0.02%
76,054
-76,056
-50% -$715K
MYGN icon
173
Myriad Genetics
MYGN
$507M
$538K 0.02%
18,805
-1,744
-8% -$50.8K
CBAY
174
DELISTED
Cymabay Therapeutics
CBAY
$451K 0.02%
88,102
– –
IMGN
175
DELISTED
Immunogen Inc
IMGN
$407K 0.02%
168,190
– –
5 6
7
8 9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Tekla Capital Management held 210 positions worth $2.29B, down 6.5% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2019 filing shows 13 new, 53 increased, 56 reduced and 18 closed positions. Its largest new stake was Insmed: 164,786 shares worth $2.91M. The largest sale was Amgen, an estimated $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2019 buy was Insmed: 164,786 shares worth $2.91M.
  • Tekla Capital Management added most to Merck in Q3 2019, an estimated $16.6M increase.
  • Tekla Capital Management's biggest Q3 2019 reduction was Amgen, cutting an estimated $18.7M.
  • Tekla Capital Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $15M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.29B portfolio in Q3 2019.
  • Tekla Capital Management opened 13 new positions and closed 18 in Q3 2019.
  • Tekla Capital Management's portfolio value fell 6.5% quarter-over-quarter to $2.29B.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.